Abstracts from 2014 through the most recent CROI can be viewed in this searchable database once they have been presented at the conference. Abstract Contents: The searchable database includes abstract text as submitted by the authors prior to CROI. Study data might be updated during the presentation at CROI. Please refer to the electronic poster or webcast for updates. Searching the Abstract Database: Enter the criteria below and click the “Search” button. After the search has been entered, the results will appear below the search form.
CROI conference materials (eg, the conference program, Abstract eBook, electronic posters, CROI logo, etc) are protected by copyright. Permission to replicate or reproduce these elements, in whole or in part, must be obtained from the CROI Conference Manager, the International Antiviral Society-USA (IAS-USA). Study data (including figures within abstracts or electronic posters) are the property of the study authors. Permission to use data and figures cannot be given by IAS–USA unless it is for regulatory reasons. For more information, please email CROIabstracts@iasusa.org.
1277 Results
Background HIV prevalence among South African AGYW increases by 10% as young women reach ages 20 to 24, highlighting the need to intervene during adolescence and emerging adulthood. PrEP for HIV prevention promises to reduce HIV incidence. However, its impact may be tempered by structural barriers and individual-level barriers. Few evaluations of multilevel interventions to support…
Background Despite reaching the UNAIDS 95-95-95 targets, many countries continue to face significant challenges with Interruption in Treatment (IIT). This analysis examines IIT rates from Fiscal years (FY) 2021 to 2024 across nine PEPFAR-supported countries—Botswana, Eswatini, Kenya, Lesotho, Malawi, Namibia, Rwanda, Zambia, and Zimbabwe—that have achieved or are nearing these targets. We explore IIT trends…
Background Retention in care remains a significant challenge for People Living with HIV (PLHIV) in Tanzania, possibly worsened by internalized HIV stigma and other factors leading to lower clinic attendance and treatment failure despite existing interventions. Financial incentives have emerged as a promising intervention for addressing social determinants of health potentially mitigating internalized HIV stigma…
Background Little is known about cabotegravir (CAB) HIV pre-exposure prophylaxis (PrEP) care disparities. We characterized injectable CAB PrEP discontinuations at a safety-net, primary care center. Methods We extracted data from electronic health records and a dashboard (Relevant®) at Whitman-Walker Health’s peer PrEP Specialist program (Washington, D.C.) from March 2022 to March 2024. The primary outcome…
Background Data are limited on effectiveness of dolutegravir (DTG)-based regimens among people living with HIV who inject drugs (PWID) in sub-Saharan Africa. We longitudinally studied PWID in Kenya taking DTG and assessed viral non-suppression and drug resistance. Methods Kenyan PWID on DTG for >6 months were enrolled, and plasma HIV RNA viral load (VL) was measured…
Background In Africa, adolescent girls and young women (AGYW) have high risk of HIV acquisition and low engagement in prevention programs. Knowledge of HIV-negative status, paired with peer support, might motivate AGYW—who have tight social connectivity and are influenced by peers—to initiate HIV prevention services, including pre-exposure prophylaxis (PrEP). Methods We conducted a cluster-randomized controlled…
Background Emergency Departments (EDs) are a major source of medical care for people living with HIV (PLWH) in the United States. PLWH who are out of care (OOC) experience poorer health outcomes and contribute to more than 40% of HIV transmissions. Gilead Sciences’ FOCUS program is a public health initiative that supports healthcare institutions to implement…
Background People who inject drugs (PWID) in the US have high HIV incidence and fatal overdose rates, yet uptake is low for pre-exposure prophylaxis (PrEP; 1%) and medications for opioid use disorder (MOUD; 18%). Long-acting PrEP and MOUD formulations may improve uptake and adherence. Methods Using the validated MYRIAD multimorbidity microsimulation model (accounting for impact…
Background On 9th February, 2024, Zambia launched the use of Cabotegravir Long-Acting (CAB-LA) for HIV prevention, as an additional layer to oral PrEP The aim was to expand HIV prevention options for high-risk individuals and address challenges with oral PrEP such as inconsistent use due to pill burden, privacy issues and stigma. However, within 6…
Background Cabotegravir/rilpivirine (CAB/RPV), the first complete long-acting injectable (LAI) antiretroviral therapy (ART) regimen, was approved by the FDA in January 2021 and offers a convenient monthly to bimonthly alternative to daily oral ART with the potential to improve adherence and viral suppression. To understand the degree of uptake of CAB/RPV, we assessed trends of and characteristics…